Opthea Limited (OPT)
NASDAQ: OPT · Real-Time Price · USD
3.502
+0.142 (4.21%)
Sep 18, 2024, 4:00 PM EDT - Market closed

Company Description

Opthea Limited, a clinical-stage biopharmaceutical company, develops and commercializes drugs for eye diseases in Australia and the United States.

Its development activities are based on the intellectual property portfolio covering vascular endothelial growth factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.

The company’s lead product candidate is sozinibercept (OPT-302), a biologic drug in Phase 3 clinical trials designed to inhibit VEGF-C and VEGF-D and complement VEGF-A inhibitors for the treatment of wet age-related macular degeneration and diabetic macular edema.

It serves the biotechnology and healthcare industries. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015.

Opthea Limited was incorporated in 1984 and is headquartered in South Yarra, Australia.

Opthea Limited
Opthea logo
Country Australia
Founded 1984
IPO Date Oct 16, 2020
Industry Biotechnology
Sector Healthcare
Employees 33
CEO Frederic Guerard

Contact Details

Address:
650 Chapel Street, Suite 0403, Level 4
South Yarra, VIC 3141
Australia
Phone 61 3 9826 0399
Website opthea.com

Stock Details

Ticker Symbol OPT
Exchange NASDAQ
Fiscal Year July - June
Reporting Currency USD
IPO Price $13.50
CIK Code 0001815620
CUSIP Number 68386J208
ISIN Number US68386J2087
SIC Code 2836

Key Executives

Name Position
Frederic Guerard Chief Executive Officer
Daniel Geffken Chief Financial Officer

Latest SEC Filings

Date Type Title
Sep 18, 2024 6-K Report of foreign issuer
Sep 10, 2024 6-K Report of foreign issuer
Sep 9, 2024 6-K Report of foreign issuer
Sep 5, 2024 6-K Report of foreign issuer
Sep 3, 2024 6-K Report of foreign issuer
Aug 30, 2024 20-F Annual and transition report of foreign private issuers
Aug 30, 2024 6-K Report of foreign issuer
Aug 8, 2024 6-K Report of foreign issuer
Jul 17, 2024 6-K Report of foreign issuer
Jul 15, 2024 6-K Report of foreign issuer